Rational Vaccines, Inc. articles

Study to be conducted at two leading research institutions in the U.K.

Results will inform protocol design of Phase 1/2 clinical trial of Company`s lead HSV-2 therapeutic vaccine candidate

WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the launch of a clinical

Rational Vaccines said findings from a pilot study showed that RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine in animal studies.

Rational`s Experimental Herpes Vaccine Shows Preclinical Promise

Rational Vaccines said findings from a pilot study showed that RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine in animal studies.

RVx201 Herpes Vaccine Description 2022

RVx201 is a first-in-human herpes simplex virus type 2 (HSV-2) live-attenuated therapeutic vaccine modified to be interferon sensitive that destroys the ability of the virus to inhibit

Founder and CEO, Agustin Fernand of Rational Vaccines that is developing a vaccine for herpes. 

There is a pandemic raging across the world – and it has nothing to do with a coronavirus. Approximately 500 million people worldwide suffer from genital herpes. Several billion more have an oral herpes infection. Herpes is a life-

Abstract

Herpes simplex virus type-1 (HSV-1) can cause severe ocular infection and blindness. We have previously shown that the HSV-1 VC2 vaccine strain is protective in mice and guinea pigs against genital herpes infection following vaginal challenge with HSV-1 or HSV-2. In this study, we evaluated the efficacy of VC2 intramuscular vaccination in mice against herpetic keratitis following ocular challenge with lethal human clinical strain HSV-1 (McKrae). VC2 vaccinati

Abstract
Background
Although herpes simplex viruses (HSV) are a major target for vaccine development no vaccine is currently licensed.

Methods
A live attenuated HSV virus vaccine, VC2 was compared to a subunit HSV vaccine, glycoprotein D (gD2) administered with the adjuvant, MPL/Alum using the guinea pig model of genital herpes. Three doses of intramuscular (IM) vaccine were provided followed by intra-vaginal challenge with HSV-2 at eit

The cornea is essential for vision yet highly sensitive to immune-mediated damage following infection. Generating vaccines that provide sterile immunity against ocular surface pathogens without evoking vision loss is therefore clinically challenging. Here, we tested a prophylactic live-attenuated vaccine against herpes simplex virus type 1 (HSV-1), a widespread human pathogen that can cause corneal blindness. Parenteral vaccination of mice resulted in sterile immunity to subsequent HSV-1 chal

ABSTRACT

Background: Although development of an HSV vaccine is a priority there is currently no vaccine available. The recent failure of subunit vaccines suggest that presentation of more antigens via a live attenuated vaccine may be required for protection. We therefore evaluated VC2. a live attenuated HSV vaccine, engineered to be unable to enter into neuronal axons.

Methods: VC2 pathogenesis was first evaluated in guinea pigs following intr

In the span of seven days, Mel Smith left her verbally abusive boyfriend, moved out of their house with her 13-year-old son, and found out that she had contracted genital herpes.

“I didn’t know what it was. I didn’t know what to do,” she says, remembering the time five years ago when her vagina itched so badly she couldn’t wear underwear. Her diagnosis? Herpes simplex virus.

The